Compugen 2025: Cash Bought Time, Not Proof

Understanding the Company

At first glance, Compugen looks like a biotech company that finally crossed the survival line. In 2025 it reported $72.8 million of revenue, $31.3 million of operating profit, $35.3 million of net profit, and ended the year with $145.6 million in cash, short-term deposits, and marketable securities. A quick read of the headline numbers can easily create the impression that the company has moved onto firmer economic ground.

That reading is too generous. Compugen is still not a product company. It is a clinical-stage developer living on two engines: pharma partnerships that generate upfronts, milestones, and staged accounting revenue, and a pipeline that still needs to prove it can create value beyond the deal narrative. What is working now is not product-market economics, but the company’s ability to turn scientific assets into collaboration cash and use that cash to buy time. The active bottleneck is turning time into proof: near-term funding pressure is lower, but the company still has to show that its pipeline can produce clinical evidence strong enough to support a more durable value story.

That is also why market value and trading actionability matter from the start. The current market cap is about NIS 655.6 million, while the last trading-day turnover was only about NIS 240 thousand. This is not a trivial detail. In a name whose valuation is driven by a few clinical readouts and partner updates, thin trading sharpens every narrative swing.

The economic map is simpler than it looks. There are four clinical-stage programs, but only one truly internal proof case right now: COM701, which entered the MAIA-ovarian trial in 2025, with an interim analysis expected in the first quarter of 2027. COM902 remains in the clinic, but management now says it does not plan to initiate new trials at this stage. GS-0321 is licensed to Gilead, yet Compugen still runs and funds Phase 1. Rilvegostomig is developed by AstraZeneca, and it is already more than a future option, it is also the source of the cash injection that reshaped 2025 through the December amendment.

Events and Triggers

AstraZeneca: This is the event that largely explains 2025 on its own. On December 16, 2025, Compugen amended the license agreement and sold AstraZeneca part of its future royalty interest in rilvegostomig for a $65 million upfront payment, while also adding $25 million to the next milestone tied to first BLA acceptance. After the amendment, the company still remains eligible for up to $195 million in future regulatory and commercial milestones and for tiered royalties up to mid-single digit. In other words, Compugen secured real oxygen, but not for free. Part of the future upside was converted into present cash.

Gilead: The second revenue engine is not product sales but clinical work. Under the December 2023 agreement, Compugen received a $60 million upfront and a further $30 million upon IND clearance, and it remains eligible for up to approximately $758 million in additional milestones plus tiered royalties from single digit to low double digit on future sales. In practice, 2025 continues to draw accounting revenue from that agreement through Phase 1 progress recognition, while most of the major cash has already been collected.

COM701: This is the real internal trigger. In 2025 the company launched MAIA-ovarian, a blinded randomized platform trial evaluating COM701 as maintenance therapy in relapsed platinum-sensitive ovarian cancer. The interim analysis is expected only in the first quarter of 2027. That means the market is getting time right now, not an answer.

COM902: Here the direction is the opposite. Management does not just acknowledge weakness in the TIGIT field, it explicitly says it does not plan to initiate new trials with COM902 for now. That is a strategic event in itself. The asset has not disappeared, but it has moved from the layer of active value drivers to the layer of optionality.

Leadership and board: In September 2025, Dr. Anat Cohen-Dayag moved from CEO to Executive Chair, and Dr. Eran Ophir became CEO. In February 2026, Dr. Michele Holcomb joined the board as an independent director. This is more than cosmetic. Once the company moves from a survival question to a capital allocation and value-capture question, governance matters more for prioritization, partnering, and strategic discipline.

Efficiency, Profitability and Competition

The central insight is that 2025 profit looks sharp, but its quality is completely different from profit in a normal operating business. Revenue jumped to $72.8 million from $27.9 million, and net result moved to $35.3 million of profit from a $14.2 million loss in 2024. But that jump was driven almost entirely by two sources: the $65 million AstraZeneca upfront and $7.8 million of Phase 1 services revenue recognized for Gilead.

Put differently, 2025 does not show that the business has become commercial. It shows that the company knows how to monetize parts of its pipeline through collaborations and recognize revenue under those contract structures. That matters, but it is not the same thing as a recurring operating engine. That is exactly what a superficial reader can miss.

What actually improved

The good part of the report is that net R&D expense fell 8% to $22.8 million, after already declining in 2024, while the company wound down earlier trials and still launched MAIA-ovarian. G&A also fell 6% to $8.9 million. This is not an operating turnaround, but it does reflect reasonable cost discipline.

The problem is that these numbers do not yet create ordinary operating leverage. They mostly reduce the burn around the pipeline. In a pre-revenue biotech name like this, efficiency is not measured only by lower spending, but by the ability to extend runway without hollowing out the development story. 2025 did that.

Where competition really matters

Compugen operates in a field where a competitor’s failure can destroy value even if its own asset has not failed. COM902 is the clearest example. Management explicitly links the decision not to initiate new trials to negative data in the TIGIT field, including the discontinuation of the Arcus and Gilead STAR-221 study for futility. That matters because it shows that even a technically viable asset can be repriced by the condition of the field around it.

COM701 and GS-0321 still live in crowded clinical areas, but there the question is less about field sentiment and more about differentiation. Can either program generate a signal strong enough to attract capital, a partnership step-up, or a stronger development path? In a product company that would be a market share discussion. Here it is still a question of clinical legitimacy.

Quality of earnings versus quality of business

This is the key data point: 71% of operating expenses in 2025 were still R&D, and 53 of the company’s 75 full-time employees at year-end were in R&D. That is a reminder that the company has not changed its basic nature. It is still spending people, time, and money in order to reach scientific proof. That is why 2025 profit does not change the core economic question. It only buys more time to face it.

Cash Flow, Balance Sheet and Capital Structure

The right frame here is all-in cash flexibility. Not how much profit was recognized, but how much real room is left after actual cash uses. In Compugen’s case that is the more relevant lens anyway, because this is not a financial-debt story. It is a liquidity, dilution, and proof-timing story.

At the end of 2025 the company held $90.6 million in cash and cash equivalents, $45.8 million in short-term deposits, and $9.3 million in marketable securities, a combined $145.6 million. At the end of 2024, the same three buckets totaled $103.3 million. That is a major improvement and it clearly reduces near-term financing pressure.

But the price has to sit next to the benefit. In 2025 Compugen sold 4.86 million shares through its ATM facility for net proceeds of $10.5 million. Since the facility was opened at the start of 2023, it has raised $14.2 million net and issued 7.77 million shares through it. So even in the year when the balance sheet strengthened, the company still relied not only on pharma cash but also on dilution.

Cash flow tells the truth

Operating cash flow was positive at $31.6 million. On the surface that looks like proof that the liquidity problem is over. In practice, the company itself explains that the year-over-year change was driven mainly by the $65 million collected from AstraZeneca in 2025, versus $91.5 million collected in 2024 from Gilead and AstraZeneca combined, net of withholding tax. That is a polite way of saying that operating cash flow is still partnership-driven, not generated by a self-funding business model.

If one analytically strips out the $65 million AstraZeneca payment, operating cash flow would still be negative by roughly $33 million. That arithmetic does not diminish the importance of the cash. It explains why the cash matters. It did not prove a new business model, it bought runway.

No financial debt wall, but there is an earnings-quality issue

On the debt side, the news is good. There is no financial debt wall here. Lease obligations total only $3.5 million, with $721 thousand due within one year. That is not the pressure point. Equity also jumped to $102.7 million from $54.9 million. So the capital-structure discussion has to be read through dilution rather than leverage.

There is also a contingent royalty obligation to the Israel Innovation Authority of about $8.3 million as of year-end 2025, but this is not immediate bank-style debt service. It matters because it reminds investors that not all future revenue will flow cleanly to shareholders, and that there are still know-how transfer and manufacturing restrictions in the background.

Deferred revenue is an accounting bridge, not new cash

At the end of 2025 the balance sheet carried $35.9 million of deferred revenue, down from $43.7 million at the end of 2024. This is a very important quality-of-earnings point. Some future reported revenue is already sitting on the balance sheet because cash came in earlier, mainly through Gilead, and will be recognized over time as Phase 1 progresses. So 2026 may still show respectable revenue without equivalent fresh cash coming in. Anyone reading only the income statement can miss the difference between cash arriving now and accounting revenue being released from the balance sheet.

Outlook

Before going deeper, four non-obvious findings define the right way to read 2025 and frame 2026:

• 2025 profit is not the beginning of a profit engine, it is the monetization of optionality. Almost all of the year’s revenue came from the AstraZeneca amendment and staged recognition under the Gilead agreement.
• The liquidity question moved down one level, but it was replaced by a value-capture question. The company bought time, but it also sold part of future upside and kept using ATM dilution.
• Internal value concentration is higher than it appears. COM902 has effectively dropped into the option layer, rilvegostomig depends on AstraZeneca, and GS-0321 depends on Gilead. That leaves COM701 as the main internal proof asset.
• Deferred revenue can keep supporting accounting performance before there is any hard new clinical value proof. That is the gap shareholders need to keep in mind.

2026 is a bridge year, not a proof year

There is not much room for interpretation here. The MAIA-ovarian interim analysis is expected only in the first quarter of 2027. That makes 2026 a clear bridge year. The market will have to live in the meantime on secondary signals: pace and quality of trial execution, Phase 1 progress for GS-0321, and continued external value building through rilvegostomig.

That creates a year in which the financial statements can still look stable, while the underlying economic question remains unresolved. If Compugen gets through 2026 with controlled burn, clean execution, and reasonable signals from the two partnered channels, it will enter 2027 from a better position. But without a meaningful clinical data point, this is still largely option maintenance.

What must happen in COM701

COM701 is the asset the company truly has to prove itself. MAIA-ovarian matters not only scientifically but strategically. After years in which Compugen was built around its discovery platform and development capability, the market now needs to see whether one internally controlled asset can get closer to a stage where value is driven by improving clinical probability, not just by licensing narratives.

If the trial progresses smoothly and the company keeps spending discipline intact until the interim analysis, market interpretation can improve even before the result itself. If there are delays, budget slippage, or signs that the study is not moving as expected, confidence will erode faster than the cash balance would suggest.

What really remains in AstraZeneca

The report does two things at once here. On one hand it sharply reduces cash pressure through the $65 million upfront. On the other hand it implicitly acknowledges that the company was willing to sell part of future upside in order to secure certainty now. That is rational, but it is not one-directional.

The positive side is clear: no near-term financing pressure, plus up to $195 million of regulatory and commercial milestones still available, including the added $25 million attached to first BLA acceptance. The less comfortable side is that Compugen no longer sits on the full original upside layer in rilvegostomig. So success in rilvegostomig can still create value, just less than before the amendment.

The point the market may miss is that this is not only a cash extraction event, but also a partial confidence signal from AstraZeneca. If AstraZeneca wanted only to squeeze price, it would not have paid $65 million upfront and increased the next milestone by $25 million. Still, that signal does not cancel the field-level TIGIT risk, especially when Compugen itself has downgraded COM902 into a waiting asset.

What Gilead has to validate in practice

GS-0321 looks large on paper, with up to $758 million in additional milestones and future royalties. But for shareholders today, that headline number matters less than the practical question: will Phase 1 progress strongly enough for Gilead to meaningfully deepen its commitment?

Compugen is still carrying the Phase 1 cost, including drug supply, while Gilead provides zimberelimab for the trial. That means Compugen is currently both funding the work and recognizing revenue over its progress. This can produce reasonably attractive financial optics, but real value proof only arrives if the trial generates evidence that makes Gilead want to take the asset further with conviction.

What can change the market reading in the near term

Over the next days, weeks, and quarters, the market is likely to focus on four things:

1. Whether the strengthened cash runway can be preserved without another aggressive financing move.
2. Whether COM701 and GS-0321 continue to progress at a pace that justifies waiting for data.
3. Whether AstraZeneca delivers external updates on rilvegostomig that support the value still left in milestones and royalties.
4. Whether COM902 remains only optionality, or whether something external pulls it back into the active discussion.

So 2026 is not the year to ask whether the company is profitable. That is the wrong question. The right question is whether cash, discipline, and partner support can bring the company to the next proof point without forcing it to sell too much more of the future in order to fund the present.

Risks

The first risk is clinical concentration. In practice, most future value is tied to a very small number of events: MAIA-ovarian, Phase 1 of GS-0321, and continued progress in rilvegostomig at AstraZeneca. A meaningful failure or delay in any one of them would not only hurt projections, it would hit the core thesis.

The second risk is partner dependence. Compugen explicitly states that its business model depends on collaboration agreements and the ability to generate revenue from them. AstraZeneca and Gilead are not merely important partners, they are part of the company’s economics. If either one slows down, terminates, or reduces commitment, the knock-on effect on value can be large.

The third risk is repeated dilution. Management believes liquidity is sufficient into 2029 based on current plans, but it also says that if plans change or burn rises, that runway could shorten. At the same time, the company has already shown that it uses the ATM as a live funding tool. Lower funding pressure does not mean dilution risk is gone.

The fourth risk is market volatility with limited tradability. In 2025 the Nasdaq share price ranged between $1.18 and $2.57, and the company itself highlights sensitivity to financings, clinical progress, and partner news. Add thin local trading on top of that, and every thesis event can move faster than the financial statements alone would suggest.

The fifth risk is that not all created value is accessible. Selling part of the rilvegostomig royalty stream, the Innovation Authority royalty overhang, and the partnered structure around GS-0321 all remind investors that the path from “good asset” to “value that reaches common shareholders” is not frictionless. That does not mean there is no value. It means the route to it runs through partners, contracts, and capital allocation, not only through science.

Conclusions

Compugen exited 2025 in a better position than it entered. The balance sheet is stronger, immediate liquidity fear has eased, and two global pharma partners still keep key parts of the story alive. But the core of the story has not changed: this is still a pre-commercial biotech company whose value will be set by its ability to turn time and cash into clinical proof.

The central blocker is no longer survival itself, but whether the company can reach 2027 with enough cash, enough credibility, and enough supporting signals to make the wait for COM701 data feel justified. In the short to medium term, the market is likely to react more to the quality of the value left after monetization and dilution than to the 2025 profit line itself.

Current thesis in one line: 2025 bought Compugen real time and removed near-term funding pressure, but it still did not prove that the company can turn that time into clinical and economic value that remains with shareholders.

What changed: the reading has shifted from liquidity fear to value capture. The older question was whether the company would need to raise quickly. The current question is how much upside remains after partial monetization, accounting recognition, and continued dilution.

Counter-thesis: one can argue that this caution is too strict, because a company with $145.6 million of liquidity, an active AstraZeneca collaboration, an active Gilead collaboration, and a central internal study already running has moved far enough away from the danger zone that the remaining optionality is still not fully reflected.

What could change the market interpretation in the short to medium term: smooth MAIA-ovarian execution, signs of deeper Gilead commitment around GS-0321, and any material rilvegostomig update from AstraZeneca could improve the read. On the other side, faster burn, more dilution, or another meaningful setback in the TIGIT field would weigh quickly.

Why this matters: because Compugen is no longer judged only by how much time it has left, but by the quality of the way it uses that time.

What must happen over the next 2 to 4 quarters: the company needs to keep spending discipline, move GS-0321 Phase 1 and MAIA-ovarian forward without major execution issues, and reach 2027 without having to sell another meaningful slice of the future in order to fund the present. What would weaken the thesis is a mix of clinical delay, renewed dilution, or weakening engagement from a core partner.